Correlation Between Sprint Bioscience and Annexin Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Sprint Bioscience and Annexin Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sprint Bioscience and Annexin Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sprint Bioscience AB and Annexin Pharmaceuticals AB, you can compare the effects of market volatilities on Sprint Bioscience and Annexin Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sprint Bioscience with a short position of Annexin Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sprint Bioscience and Annexin Pharmaceuticals.

Diversification Opportunities for Sprint Bioscience and Annexin Pharmaceuticals

-0.44

Correlation Coefficient

Sprint Bioscience  Annexin Pharmaceuticals

Very good diversification

The 3 months correlation between Sprint and Annexin is -0.44. Overlapping area represents the amount of risk that can be diversified away by holding Sprint Bioscience AB and Annexin Pharmaceuticals AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Annexin Pharmaceuticals and Sprint Bioscience is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sprint Bioscience AB are associated (or correlated) with Annexin Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Annexin Pharmaceuticals has no effect on the direction of Sprint Bioscience i.e., Sprint Bioscience and Annexin Pharmaceuticals go up and down completely randomly.

Pair Corralation between Sprint Bioscience and Annexin Pharmaceuticals

Assuming the 90 days trading horizon Sprint Bioscience AB is expected to generate 1.03 times more return on investment than Annexin Pharmaceuticals. However, Sprint Bioscience is 1.03 times more volatile than Annexin Pharmaceuticals AB. It trades about 0.13 of its potential returns per unit of risk. Annexin Pharmaceuticals AB is currently generating about 0.0 per unit of risk. If you would invest  131.00  in Sprint Bioscience AB on September 2, 2024 and sell it today you would earn a total of  51.00  from holding Sprint Bioscience AB or generate 38.93% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Sprint Bioscience AB  vs.  Annexin Pharmaceuticals AB

Sprint Bioscience

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Sprint Bioscience AB are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Sprint Bioscience sustained solid returns over the last few months and may actually be approaching a breakup point.

Annexin Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Annexin Pharmaceuticals AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Annexin Pharmaceuticals is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Sprint Bioscience and Annexin Pharmaceuticals

The main advantage of trading using opposite Sprint Bioscience and Annexin Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sprint Bioscience position performs unexpectedly, Annexin Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Annexin Pharmaceuticals will offset losses from the drop in Annexin Pharmaceuticals' long position.

The idea behind Sprint Bioscience AB and Annexin Pharmaceuticals AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.